Phase III Clinical Study of JTE-052A - Randomized Controlled and Long-term Extension Study in Patients with Atopic Dermatitis -
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Delgocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Japan Tobacco
- 12 Jan 2018 According to a Japan Tobacco media release, data from this study with other ongoing phase 3 studies will be used to submit a marketing application for JTE-052 ointment in Japan.
- 12 Jan 2018 According to a Japan Tobacco media release, Primary endpoint (change of the mEASI score from baseline) has been met.
- 05 Sep 2017 Status changed from recruiting to active, no longer recruiting.